Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Pilatus Biosciences Announces Hong Kong Clinical Trial Application Approval for PLT012 and Expansion into Hong Kong
4+ hour, 51+ min ago (444+ words) BioSpace Pilatus Biosciences Announces Hong Kong Clinical Trial Application Approval for PLT012 and Expansion into Hong Kong CTA approval marks an important milestone in advancing PLT012 into the clinic and strengthens the Company's presence in one of Asia’s leading biotech hubs DOVER,…...
Ashlins Pharmaceuticals and Lee's Pharm Announce Exclusive License and Supply Agreement Valued at Up to $31 Million
7+ hour, 36+ min ago (334+ words) BioSpace Ashlins Pharmaceuticals and Lee’s Pharm Announce Exclusive License and Supply Agreement Valued at Up to $31 Million Lee’s is eligible to receive up to $31 million in upfront and milestone payments. NEW YORK--(BUSINESS WIRE)--Ashlins Pharmaceuticals today announced that its…...
Altesa BioSciences Welcomes Seasoned Biotech Leader Brett Haumann, MBBCh, MBA as Chief Executive Officer
7+ hour, 42+ min ago (477+ words) BioSpace Altesa BioSciences Welcomes Seasoned Biotech Leader Brett Haumann, MBBCh, MBA as Chief Executive Officer Dr. Haumann brings decades of respiratory drug expertise to support next phase of company growth CEO appointment follows recent clinical and corporate milestones including Phase…...
Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer
8+ hour, 14+ min ago (331+ words) SAN DIEGO, July 21, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, has expanded their clinical trial collaboration with Merck (known as MSD outside of the US and Canada) to…...
Verismo Therapeutics Expands KIR-CAR Solid Tumor Treatment Pipeline with Novel Binder Developed at Penn Targeting Claudin 6 (CLDN6)
6+ hour, 39+ min ago (855+ words) BioSpace Verismo Therapeutics Expands KIR-CAR Solid Tumor Treatment Pipeline with Novel Binder Developed at Penn Targeting Claudin 6 (CLDN6) - Verismo's KIR-CAR pipeline now spans two solid tumor antigens: mesothelin, targeted by the clinical-stage SynKIR™-110 in the STAR-101 Phase 1 trial, and CLDN6, targeted by…...
TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology
21+ hour, 27+ min ago (184+ words) TriLink's Complete Portfolio of CleanCap® Analogs are Patented in Major Jurisdictions Globally; TriLink is the Sole Authorized Manufacturer of CleanCap® Capping Analogs The allowed claims are directed to co-transcriptional RNA synthesis methods utilizing either trimer or tetramer capping structures. This…...
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
6+ hour, 36+ min ago (165+ words) BioSpace Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4 GERMANTOWN, Md., July 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today…...
Estrigenix Therapeutics Announces Series Seed Financing to Advance ERβ Platform Across Women's Health and Neurodegenerative Diseases
6+ hour, 25+ min ago (313+ words) BioSpace Estrigenix Therapeutics Announces Series Seed Financing to Advance ERβ Platform Across Women’s Health and Neurodegenerative Diseases MILWAUKEE--(BUSINESS WIRE)--Estrigenix Therapeutics today announced the first closing of its $2M Series Seed financing, led by Talents Fund I. The financing provides…...
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
44+ min ago (290+ words) Samsung Biologics has offered to buy PolyPeptide for CHF 1.46 billion ($1.8 billion), marking a move into peptide manufacturing. Revenue growth at PolyPeptide, a Swiss contract development and manufacturing organization (CDMO), is accelerating amid rising demand for peptides, particularly in metabolic diseases…...
Cellares and Papillon Therapeutics Partner to Automate Manufacturing of PPL-001 for Patients With Friedreich’s Ataxia
6+ hour, 19+ min ago (719+ words) BioSpace Cellares and Papillon Therapeutics Partner to Automate Manufacturing of PPL-001 for Patients With Friedreich’s Ataxia Collaboration will apply Cellares’ Cell Shuttle® and Cell Q™ platforms to PPL-001, an investigational hematopoietic stem cell therapy for a rare multi-systemic pediatric disease…...